Yung-Jue Bang, MD
Patients with operable gastric cancer had significant improvement in disease-free survival (DFS) with adjuvant capecitabine plus oxaliplatin (Xelox) following definitive surgery, according to results of a large international trial.
Table. Stratified 3-Year Disease-Free Survival Rates
Stage of disease
... to read the full story